Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis

An intensive short-term chemotherapy regimen has substantially prolonged the overall survival of Burkitt’s lymphoma (BL) patients, which has been further improved by addition of rituximab. However, the inevitable development of resistance to rituximab and the toxicity of chemotherapy remain obstacle...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xiaowen, Chen, Jianfeng, Li, Ling, Ding, Peipei, Wang, Qi, Zhang, Wei, Li, Luying, Lv, Xinyue, Zhou, Danlei, Jiang, Zhengzeng, Zeng, Haiying, Xu, Yifan, Hou, Yingyong, Hu, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315025/
https://www.ncbi.nlm.nih.gov/pubmed/30584254
http://dx.doi.org/10.1038/s41419-018-1259-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315025/
https://www.ncbi.nlm.nih.gov/pubmed/30584254
http://dx.doi.org/10.1038/s41419-018-1259-5

Ejemplares similares